- Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a clinical data in advanced metastatic colorectal cancer (CRC) are anticipated in the first half of 2025 -
- Early-stage research and platform capabilities to be concentrated on existing and potential future partnerships during 2025 -
- Revised focus and associated cost and headcount reductions expected to extend cash runway into the second quarter of 2026 -
- Company to present at 43rd Annual JP Morgan Healthcare Conference on January 15th -
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.